Hims & Hers plans big peptide push, BPC-157 included

Telehealth giant Hims & Hers announced plans to rapidly expand into six experimental peptide therapies, including BPC-157 and TB-500. This move signals a significant push into advanced longevity and recovery treatments, aiming to capture a growing market for compounds beyond traditional medications. It's a clear signal for where direct-to-consumer health is heading next.